
Exact Sciences Investor Relations Material
Latest events

Q2 2025
Exact Sciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Exact Sciences Corporation
Access all reports
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States. The company operates through its three business segments: Colorectal Cancer Screening, Breast Cancer Detection, and ColoPath Products. It offers Cologuard, a diagnostic colon test for preventing colorectal cancer;Virtual Colonoscopy, a colorectal cancer screening test that uses 5-10 minutes of transmission of images of the digestive tract to provide virtual visualization of intestines; Cologuard GI, which offers Cologuard to patients at a subsidized price; and Fecal DNA Test that is designed to screen patients at high risk for hereditary nonpolyposis colorectal cancers (Lynch syndrome) or people who are not candidates for Virtual Colonoscopy. Exact Sciences Corporation is based in Madison, Wisconsin.
Key slides for Exact Sciences Corporation


Corporate Presentation
Exact Sciences Corporation


Q2 2025
Exact Sciences Corporation
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
EXAS
Country
🇺🇸 United States